Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001012975-18-001091
Filing Date
2018-10-04
Accepted
2018-10-04 16:06:30
Documents
1
Period of Report
2018-10-02

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edgar.html 4  
1 PRIMARY DOCUMENT edgar.xml 4 3013
  Complete submission text file 0001012975-18-001091.txt   5414
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-32587 | Film No.: 181108000
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-32587 | Film No.: 181107999

Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Issuer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations